Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience
Abstract Background In GM1 gangliosidosis the lack of function of β‐galactosidase results in an accumulation of GM1 ganglioside and related glycoconjugates in visceral organs, and particularly in the central nervous system, leading to severe disability and premature death. In the type 2 form of the...
Main Authors: | Rita Fischetto, Valentina Palladino, Maria M. Mancardi, Thea Giacomini, Stefano Palladino, Alberto Gaeta, Maja Di Rocco, Lucia Zampini, Giuseppe Lassandro, Vito Favia, Maria E. Tripaldi, Pietro Strisciuglio, Alfonso Romano, Mariasavina Severino, Amelia Morrone, Paola Giordano |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Molecular Genetics & Genomic Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/mgg3.1371 |
Similar Items
-
Brain ceramide hexosides in Tay-Sachs disease and generalized gangliosidosis (GM1-gangliosidosis)
by: Kunihiko Suzuki, et al.
Published: (1967-03-01) -
Progressive dystonia as a presenting manifestation of GM1 gangliosidosis
by: Sahil Mehta, et al.
Published: (2019-01-01) -
GM1 gangliosidosis associated with neonatal-onset of diffuse ecchymoses and mongolian spots
by: Imad Dweikat, et al.
Published: (2011-01-01) -
Feasibility study of cyclodextrins as active pharmaceutical ingredients for the treatment of GM1-gangliosidosis
by: Yuki Maeda, et al.
Published: (2016-02-01) -
GM1 Gangliosidosis Type 1 and Mongolian Spots
by: J Gordon Millichap
Published: (2013-06-01)